These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35093636)

  • 1. BLU-554, A selective inhibitor of FGFR4, exhibits anti-tumour activity against gastric cancer in vitro.
    Zhang X; Zhang X; Han R; Wang Z; Yang Q; Huang Y; Yan Y
    Biochem Biophys Res Commun; 2022 Mar; 595():22-27. PubMed ID: 35093636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
    Xie M; Lin Z; Ji X; Luo X; Zhang Z; Sun M; Chen X; Zhang B; Liang H; Liu D; Feng Y; Wang Y; Li Y; Liu B; Huang W; Xia L
    J Hepatol; 2023 Jul; 79(1):109-125. PubMed ID: 36907560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation.
    Luo Y; Yang C; Lu W; Xie R; Jin C; Huang P; Wang F; McKeehan WL
    J Biol Chem; 2010 Sep; 285(39):30069-78. PubMed ID: 20657013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of the FGFR4 inhibitor PD173074 and 5-fluorouracil reduces proliferation and promotes apoptosis in gastric cancer.
    Ye YW; Hu S; Shi YQ; Zhang XF; Zhou Y; Zhao CL; Wang GJ; Wen JG; Zong H
    Oncol Rep; 2013 Dec; 30(6):2777-84. PubMed ID: 24126887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing of FGFR4 could influence the biological features of gastric cancer cells and its therapeutic value in gastric cancer.
    Ye Y; Jiang D; Li J; Wang M; Han C; Zhang X; Zhao C; Wen J; Kan Q
    Tumour Biol; 2016 Mar; 37(3):3185-95. PubMed ID: 26432329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
    Hatlen MA; Schmidt-Kittler O; Sherwin CA; Rozsahegyi E; Rubin N; Sheets MP; Kim JL; Miduturu C; Bifulco N; Brooijmans N; Shi H; Guzi T; Boral A; Lengauer C; Dorsch M; Kim RD; Kang YK; Wolf BB; Hoeflich KP
    Cancer Discov; 2019 Dec; 9(12):1686-1695. PubMed ID: 31575540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-cancer effects of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives on hepatocellular carcinoma harboring FGFR4 activation.
    Nam Y; Shin I; Kim Y; Ryu S; Kim N; Ju E; Sim T
    Neoplasia; 2022 Jan; 24(1):34-49. PubMed ID: 34864570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
    Liu Y; Chen X; Luo Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors.
    Pan C; Nie W; Wang J; Du J; Pan Z; Gao J; Lu Y; Che J; Zhu H; Dai H; Chen B; He Q; Dong X
    Eur J Med Chem; 2021 Dec; 225():113794. PubMed ID: 34488024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnolin Inhibits Proliferation and Invasion of Breast Cancer MDA-MB-231 Cells by Targeting the ERK1/2 Signaling Pathway.
    Wang J; Zhang S; Huang K; Shi L; Zhang Q
    Chem Pharm Bull (Tokyo); 2020; 68(5):421-427. PubMed ID: 32378540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of ERK-MAPK signaling pathway in pentagastrin-regulated growth of large intestinal carcinoma.
    Mao JD; Wu P; Huang JX; Wu J; Yang G
    World J Gastroenterol; 2014 Sep; 20(35):12542-50. PubMed ID: 25253956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing.
    Ho HK; Németh G; Ng YR; Pang E; Szántai-Kis C; Zsákai L; Breza N; Greff Z; Horváth Z; Pató J; Szabadkai I; Szokol B; Baska F; Őrfî L; Ullrich A; Kéri G; Chua BT
    Curr Med Chem; 2013; 20(10):1203-17. PubMed ID: 23409720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained ERK activation-mediated proliferation inhibition of farrerol on human gastric carcinoma cell line by G0/G1-phase cell-cycle arrest.
    Liu E; Li J; Shi S; Wang X; Liang T; Wu B; Li Q
    Eur J Cancer Prev; 2016 Nov; 25(6):490-9. PubMed ID: 26656929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The over-expression of FGFR4 could influence the features of gastric cancer cells and inhibit the efficacy of PD173074 and 5-fluorouracil towards gastric cancer.
    Li J; Ye Y; Wang M; Lu L; Han C; Zhou Y; Zhang J; Yu Z; Zhang X; Zhao C; Wen J; Kan Q
    Tumour Biol; 2016 May; 37(5):6881-91. PubMed ID: 26662569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiproliferative mechanism of a cannabinoid agonist by cell cycle arrest in human gastric cancer cells.
    Park JM; Xian XS; Choi MG; Park H; Cho YK; Lee IS; Kim SW; Chung IS
    J Cell Biochem; 2011 Apr; 112(4):1192-205. PubMed ID: 21312237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phloretin flavonoid exhibits selective antiproliferative activity in doxorubicin-resistant gastric cancer cells by inducing autophagy, inhibiting cell migration and invasion, cell cycle arrest and targeting ERK1/2 MAP pathway.
    You Q; Xu J; Zhu Z; Hu Z; Cai Q
    J BUON; 2020; 25(1):308-313. PubMed ID: 32277647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of A549 cell proliferation and metastasis by calycosin via inhibition of the PKC‑α/ERK1/2 pathway: An in vitro investigation.
    Cheng XD; Gu JF; Yuan JR; Feng L; Jia XB
    Mol Med Rep; 2015 Dec; 12(6):7992-8002. PubMed ID: 26498639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flavopereirine induces cell cycle arrest and apoptosis via the AKT/p38 MAPK/ERK1/2 signaling pathway in human breast cancer cells.
    Yeh HT; Tsai YS; Chen MS; Li YZ; Lin WC; Lee YR; Tseng YS; Sheu SM
    Eur J Pharmacol; 2019 Nov; 863():172658. PubMed ID: 31518562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554).
    Li W; Sparidans R; El-Lari M; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
    Int J Pharm; 2020 Jan; 573():118842. PubMed ID: 31759109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGF-β1 Promotes Hepatocellular Carcinoma Invasion and Metastasis via ERK Pathway-Mediated FGFR4 Expression.
    Huang J; Qiu M; Wan L; Wang G; Huang T; Chen Z; Jiang S; Li X; Xie L; Cai L
    Cell Physiol Biochem; 2018; 45(4):1690-1699. PubMed ID: 29490293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.